Skip to main content

Table 2 Comparison of AMBITION cohort with healthy controls in patient demographics and baseline biomarker levels. Differences between cohorts are shown as ANCOVA values adjusted for race differences

From: Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Variables AMBITION cohort RA patients (N = 387) Healthy controls (N = 72) Difference between cohorts
Age (years), mean (SD) 50.9 (12.9) 49.7 (6.1) ns
Female, n (%) 300 (76) 41 (76) ns
Race, no. white/black/other (%) 325 (84)/14 (4)/48 (12) 51 (71)/21 (29)/0 (0) < 0.0001
Baseline C1M (ng/mL), mean (SD) 43.4 (30.7) 18.7 (15.3) < 0.001
Baseline C2M (ng/mL), mean (SD) 0.38 (0.2) 0.3 (0.16) < 0.001
Baseline C3M (ng/mL), mean (SD) 17.8 (8.0) 11.1 (2.8) < 0.001
Baseline C4M (ng/mL), mean (SD) 50.9 (24.9) 21.5 (6.1) < 0.001
Baseline CRPM (ng/mL), mean (SD) 20.9 (12.9) 7.5 (2.1) < 0.001
Baseline CRP (ng/mL), mean (SD) 3.0 (3.5)